

OFFICIAL RECORD COPY
MATERIALS LICENSE

Amendment No. 7

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

DL-052496-06

| | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p style="text-align: center;">Licensee</p> <p>1. Meritus Health Systems, Inc.</p> <p>2. 233 Hershberger Road Suite 200 Roanoke, Virginia 24012</p> | <p>In accordance with the letter dated March 25, 1996</p> <p>3. License Number 45-25194-01</p> <p>is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration Date July 31, 2002 (extended)</p> <hr/> <p>5. Docket or Reference No. 030-32701</p> |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6. Byproduct, Source, and/or Special Nuclear Material | 7. Chemical and/or Physical Form | 8. Maximum Amount that Licensee May Possess at Any One Time Under This License |
|-------------------------------------------------------|--------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| A. Any byproduct material identified in 10 CFR 35.100 | A. Any radiopharmaceutical identified in 10 CFR 35.100 | A. As needed |
| B. Any byproduct material identified in 10 CFR 35.200 | B. Any radiopharmaceutical identified in 10 CFR 35.200, except xenon 133 | B. As needed, except no single patient dose of I-125 or I-131 to exceed 1.11 megabecquerels (30 µCi) |
| C. Uranium depleted in uranium 235 | C. Metal | C. 999 kilograms |

9. Authorized Use:

- A. Medical use in uptake, dilution and excretion studies identified in 10 CFR 35.100
- B. Medical use in imaging and localization studies identified in 10 CFR 35.200
- C. Shielding for molybdenum-99/technetium-99m generators

CONDITIONS

- 10. A. Licensed material shall be used only at temporary job locations of the licensee in Virginia and West Virginia.
- B. Notwithstanding the requirement of 10 CFR 35.80(a), the licensee may transport molybdenum-99/technetium-99m generators to temporary job locations for use only within the mobile nuclear medicine facility.

Handwritten signature/initials

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number 45-25194-01

Docket or Reference Number 90-32701

Amendment No. 7

(Continued)

CONDITIONS

10. C. Licensed materials may only be delivered to the licensee's mobile unit, the primary storage location, while at:
- (1) Page Memorial Hospital, 200 Memorial Drive, Luray, Virginia;
 - (2) Summersville Memorial Hospital, 400 Fairview Heights Road, Summersville, West Virginia; and
 - (3) Plateau Medical Center, 430 Main Street, Oak Hill, West Virginia.
 - (4) Williamson Memorial Hospital, 1950 Alderson Street, Williamson, West Virginia.
 - (5) Dickenson County Medical Center, Hospital Drive, Clintwood, Virginia.
 - (6) Community Radiology of Virginia, Inc., 2000 Leatherwood Lane, Bluefield, Virginia and/or 2001 Leatherwood Lane, Bluefield, West Virginia.
 - (7) Welsh Emergency Hospital, 454 McDowell Street, Welsh, West Virginia.
 - (8) The Heart Institute of Southern West Virginia, 110 South Court Street, Lewisburg, West Virginia.
 - (9) Grant Memorial Hospital, Route 55 West, Petersburg, West Virginia.

11. Radiation Safety Officer: Francis H. George, M.D.

| <u>Authorized users</u> | <u>Material and Use</u> |
|----------------------------------|------------------------------------------------------------------|
| A. Francis H. George, M.D. | Medical uses described in 10 CFR 35.100 and 35.200. |
| B. Mohammad Ebrahim Dehgen, M.D. | Medical uses described in 10 CFR 35.100 and 35.200. |
| C. Walter W. Wolfe, M.D. | Medical uses described in 10 CFR 35.100 and 35.200. |
| D. Ann Jackson Smith, M.D. | Technetium 99m radiopharmaceuticals for cardiac imaging studies. |
| E. Michael E. Shahan, M.D. | Medical uses described in 10 CFR 35.100 and 35.200. |
| F. Ezad N. Ahmad, M.D. | Technetium 99m radiopharmaceuticals for cardiac imaging studies. |
| G. M. R. Ramakrishnan, M.D. | Medical uses described in 10 CFR 35.100 and 35.200. |
| H. Je Hyun Kim, M.D. | Medical uses described in 10 CFR 35.100 and 35.200. |

MATERIAL LICENSE
SUPPLEMENT SHEET

License Number 45-25194-01

Docket or Reference Number 50-32701

Amendment No. 7

(Continued)

CONDITIONS

Authorized users

Material and Use

- | | | |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 12. | <ul style="list-style-type: none"> I. Steven A. Artz, M.D. J. Ali Goodarzi, M.D. K. Stephen P. Raskin, M.D. L. Emily Wang Lewis, M.D. M. F. Caryle Stebner, M.D. N. M. S. Kim, M.D. O. J. K. Kim, M.D. | <ul style="list-style-type: none"> Medical uses described in 10 CFR 35.100 and 35.200. Medical uses described in 10 CFR 35.100 and §35.200. Medical uses described in 10 CFR 35.100 and 35.200. Medical uses described in 10 CFR 35.100 and 35.200. Medical uses described in 10 CFR 35.100 and 35.200. Medical uses described in 10 CFR 35.100 and 35.200. Medical uses described in 10 CFR 35.100 and 35.200. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
13. Prior to vacating or releasing any field office or storage location authorized by this license, the licensee shall notify the Nuclear Regulatory Commission in accordance with the provisions of 10 CFR 30.36.
 14. The licensee may transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
 15. The licensee shall maintain records of information important to safe and effective decommissioning at 233 Hershberger Road, Roanoke, Virginia, pursuant to the provisions of 10 CFR 30.35(g) until this license is terminated by the Commission.
 16. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum specified 10 CFR 30.35 for establishing decommissioning financial assurance.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number 45-25194-01

Docket or Reference Number 80-32701

Amendment No. 7

(Continued)

Conditions

17. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with (Continued) the statements, representations, and procedures contained in the documents including any enclosures, listed below. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated March 4, 1992

- B. Letters dated:
- (1) April 28, 1992
 - (2) May 20, 1992
 - (3) May 26, 1992
 - (4) July 23, 1992
 - (5) September 30, 1992
 - (6) December 28, 1992
 - (7) March 15, 1994 [add place of use and delete alternate RSO]
 - (8) February 24, 1995 [add users, linearity kit, RSC structure, mobile sites]
 - (9) June 9, 1995 [added information for authorized user]
 - (10) November 22, 1995 [Add new users and new temporary jobsites]
 - (11) March 25, 1996 [Description of new mobile nuclear medicine unit]
 - (12) May 14, 1996 [Addition of two authorized users; and Addition of another hospital as a location of use]
 - (13) May 21, 1996 [Facsimile regarding deletion of an authorized user; and Extension of expiration date in accordance with 10 CFR 30.36]

C. Letter and attachments received April 19, 1993

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

EARL G. WRIGHT

DATE MAY 24 1996

BY

Earl G. Wright

Region II, Division of Nuclear Materials Safety
101 Marietta Street, N.W., Suite 2900
Atlanta, GA 30323-0199

NAMLICENSE 45-25194 A7

3/27/1996



UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION II
101 MARIETTA STREET, N.W., SUITE 2900
ATLANTA, GEORGIA 30323-0199

MAY 28 1998

INFORMATION FOR NRC MATERIAL LICENSEES

Please find enclosed: Your NRC material license
 Amendment to your NRC material license
 Amendment renewing your NRC material license
 Amendment terminating your NRC material license
 Notice for Radiographer Quality Assurance Approval Program

Please review the enclosed document carefully and be sure that you understand all conditions. If there are any errors or questions, please notify this office (ATTN: Ms. Diane Heim at (404) 331-4673) so that we can provide appropriate corrections and answers.

Please be advised that your license expires at the end of the day in the month and year stated in the license. Unless your license has been terminated, you must conduct your program involving byproduct materials in accordance with the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

1. Operate in accordance with NRC regulations 10 CFR 19, "Notice, Instructions and Reports to Workers Inspections," 10 CFR Part 20, "Standards for Protection Against Radiation," and other applicable regulations.
2. Not possess and use materials authorized in Items 6, 7, and 8, on the license until:
 - a. you have constructed the facilities and obtained the equipment described in the license application and supporting documentation; and
 - b. you have notified the U. S. Nuclear Regulatory Commission, Region II, ATTN: Materials Licensing/Inspection Branch, in writing, that activities authorized by the license will be initiated
 - c. you have submitted & certified implementation of a Quality Management Program (10 CFR 35.32) for radiotherapy, or for administering > 30 uCi of I-125 or I-131.
3. Notify NRC, in writing, within 30 days:
 - a. when an authorized user, Radiation Safety Officer, or Teletherapy Physicist permanently discontinues performance of duties under the license or has a name change; or
 - b. when the licensee's mailing address changes (no fee is required if the location of byproduct material remains the same).
4. In accordance with 10 CFR 30.36(b) and/or license condition, notify NRC, promptly, in writing, and request termination of the license:
 - a. when you decide to terminate all activities involving materials authorized under the license; or
 - b. if you decide not to complete the facility, acquire equipment, or possess and use authorized material.

5. Request and obtain a license amendment before you:
- a. receive or use byproduct material for a clinical procedure permitted under Part 35 but not permitted by your license issued pursuant to this part.
 - b. permit anyone, not authorized under 10 CFR 35, Subpart J, to work as an authorized user under a license for medical use of byproduct material.
 - c. permit anyone, not authorized under 10 CFR 35, Subpart J, to work as a Radiation Safety Officer, Teletherapy Physicist, or Nuclear Pharmacist, under a license for medical use of byproduct material.
 - d. order byproduct material in excess of the amount, or a different radionuclide or form, other than authorized on the license;
 - e. add or change the areas of use or address (or addresses) of use identified in the license application or on the license; or
 - f. change ownership of your organization.
6. Submit a complete renewal application with proper fee or termination request at least 30 days before the expiration date of your license. You will receive a reminder notice approximately 90 days before the expiration date. Possession of byproduct material after your license expires is a violation of NRC regulations. Transfer of licensed materials must be consistent with 10 CFR 30.41, 40.51 or 70.42, as applicable. A license will not normally be renewed, except on a case-by-case basis, in instances where licensed material has never been possessed or used.

In addition, please note that NRC Form 313 requires the applicant, by his/her signature, to verify that the applicant understands that all statements contained in the application are true and correct to the best of the applicant's knowledge. The signatory for the application should be the licensee or certifying official rather than a consultant.

You will be periodically inspected by NRC. Failure to conduct your program in accordance with NRC regulations, license conditions, and representations made in your license application and supplemental correspondence with NRC will result in enforcement action against you. This could include issuance of a Notice of Violation, or imposition of a Civil Penalty, or an order suspending, modifying or revoking your license as specified in the "General Statement of Policy and Procedures for NRC Enforcement Actions," NUREG-1600, (7/95). Since serious consequences to employees and the public can result from failure to comply with NRC requirements, prompt and vigorous enforcement action will be taken against those who do not achieve the necessary attention to detail and standard of compliance expected of licensees.

Thank you for your cooperation.

Enclosures:

1. NRC License
2. Category Marked Below for:
 - New licenses: NUREG-1600 (7/95); 19; 20; 30; 40 or 70, as appropriate; 71; 170; NRC Form 3; Agreement State list; and NRC Form 313.
 - New radiography licenses: Parts 34; 150.
 - New medical and teletherapy licenses: Part 35.
 - Amendments and renewals: NRC Form 313.